Print

Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies  
9/20/2012 10:22:54 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has entered into a strategic partnership with The Leukemia & Lymphoma Society® (LLS) to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies. Under the terms of the agreement, LLS will provide up to $7.5 million in funding to support Constellation’s small molecule BET inhibitor program through the completion of a broad Phase 1 clinical plan.
//-->